"Designing Growth Strategies is in our DNA"
Chikungunya is a viral disease caused due to bite of an infected mosquito. Symptoms of chikungunya are commonly identified after 3-7 days after a mosquito bite. Symptoms observed in patients with chikungunya are high fever, rashes, headache, muscle pain, joint pain, nausea, and fatigue. Chikungunya is diagnosed by a serological test. The signs of chikungunya are very similar to dengue and thus can be misdiagnosed.
Currently, there are no vaccine or drugs available to treat chikungunya. Treatment has been provided for relieving the symptoms rather than treating the cause. Over the counter (OTC) drugs such as ibuprofen, naproxen, acetaminophen helps to reduce the fever and joint pain and increase in fluid intake is recommended to the patients to prevent dehydration.
Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of chikungunya. For instance; MV-CHIK low dose is being studied by Themis Bioscience GmbH, is currently in phase 2 of clinical trial for the study to evaluate the immunogenicity, safety, and tolerability in patients with chikungunya viral infection. National Institute of Allergy and Infectious Diseases (NIAID) is conducting a study on VRC-CHKVLP059-00-VP to evaluate the immunogenicity and safety in healthy adults as chikungunya vaccine. It is currently in phase 2 of clinical trials.
To know how our report can help streamline your business, Speak to Analyst
Currently, more than 50% of the pipeline candidates for chikungunya are in phase 1 and phase 2 of clinical trials. Among these majority of studies is being sponsored by research institutes.
The report on ‘Chikungunya – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for chikungunya. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for chikungunya.
The report on ‘Chikungunya – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
US +1 833 909 2966 ( Toll Free )